The authors regret a wrong reference cited in table 2, first column with reference to the heading “Odyssey Outcomes – DM (prespecified analysis) [70]”. CURRENT VERSION OF TABLE 2 (excerpt)[Figure presented] The correct reference to be indicated with reference to the heading “Odyssey Outcomes – DM (prespecified analysis) is [64] instead of 70. Please, see the screenshot below:[Figure presented] The authors would like to apologise for any inconvenience caused.
Corrigendum to "Exploring the benefits of alirocumab as lipid-lowering therapy in people with diabetes and very high cardiovascular risk" [Diabetes Res. Clin. Pract. 222 (2025) 112055] / Avogaro, Angelo; Buzzetti, Raffaella; Candido, Riccardo; Cosmo, Salvatore De; Notarianni, Lucia; Consolo, Eleonora; Luciano, Myriam. - In: DIABETES RESEARCH AND CLINICAL PRACTICE. - ISSN 0168-8227. - (2025). [10.1016/j.diabres.2025.112177]
Corrigendum to "Exploring the benefits of alirocumab as lipid-lowering therapy in people with diabetes and very high cardiovascular risk" [Diabetes Res. Clin. Pract. 222 (2025) 112055]
Buzzetti, Raffaella;
2025
Abstract
The authors regret a wrong reference cited in table 2, first column with reference to the heading “Odyssey Outcomes – DM (prespecified analysis) [70]”. CURRENT VERSION OF TABLE 2 (excerpt)[Figure presented] The correct reference to be indicated with reference to the heading “Odyssey Outcomes – DM (prespecified analysis) is [64] instead of 70. Please, see the screenshot below:[Figure presented] The authors would like to apologise for any inconvenience caused.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
